New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 8, 2014
04:55 EDTBCR, BCR, ISIS, ISIS, TRVN, TRVN, SGEN, SGEN, ONCS, ONCS, KBIO, KBIO, GNMK, GNMK, LXRX, LXRX, ACAD, ACAD, EXAM, EXAMNeedham to hold a conference
Life Sciences Conference is being held in New York on April 8-9.
News For BCR;ACAD;LXRX;GNMK;KBIO;ONCS;SGEN;TRVN;ISIS;EXAM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 23, 2014
10:06 EDTTRVNSummer Street chief scientific officer holds an analyst/industry conference call
Subscribe for More Information
October 22, 2014
17:37 EDTBCRC.R. Bard raises FY14 EPS view to $8.34-$8.38 from $8.25-$8.35, consensus $8.31
Subscribe for More Information
17:36 EDTBCRC.R. Bard sees Q4 EPS $2.22-$2.26, consensus $2.26
Guidance provided on Q3 earnings conference call.
16:12 EDTBCRC.R. Bard reports Q3 adjusted EPS $2.15, consensus $2.10
Subscribe for More Information
15:30 EDTBCRNotable companies reporting after market close
Subscribe for More Information
05:17 EDTLXRXIpsen, Lexicon enter into ex-North America/Japan licensing agreement
Ipsen (IPSEY) and Lexicon Pharmaceuticals (LXRX) announced that they have entered into an exclusive licensing agreement for Ipsen to commercialize telotristat etiprate outside of North America and Japan, with a focus on the treatment of carcinoid syndrome. Lexicon retains sole rights to commercialize telotristat etiprate in the United States, Canada and Japan. Lexicon is conducting Phase 3 clinical trials of telotristat etiprate for carcinoid syndrome, a serious condition caused by symptomatic neuroendocrine tumors, which produce large amounts of serotonin. Carcinoid syndrome is characterized by severe diarrhea, flushing and, in some cases, heart valve damage. Telotristat etiprate is an oral, small-molecule inhibitor of tryptophan hydroxylase, or TPH, that reduces peripheral serotonin production without affecting brain serotonin levels. Telotristat etiprate has received fast track status and orphan drug designation from the FDA, and has received orphan drug designation from the European Medicines Agency. Under the financial terms of the agreement, Lexicon is eligible to receive up to $145M, comprising $23M upfront payment and additional payments contingent upon achievement of clinical, regulatory and commercial milestones. In addition, Lexicon is also eligible to receive royalties on net sales of telotristat etiprate in the licensed territory.
October 21, 2014
06:27 EDTTRVNTrevena management to meet with Needham
Subscribe for More Information
October 15, 2014
09:57 EDTISISLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
October 14, 2014
10:54 EDTTRVNTrevena management to meet with JMP Securities
Subscribe for More Information
October 13, 2014
07:12 EDTISISOligonucleotide Therapeutics Society to hold annual meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use